Ansuvimab
Ansuvimab (pronounced as an-SOO-vi-mab) is a monoclonal antibody that is used in the treatment of Ebola virus disease. It is marketed under the brand name Ebanga.
Etymology
The name "Ansuvimab" is derived from the International Nonproprietary Names (INN), which follows a certain pattern for monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "vi-" infix suggests that it is a viral target. The origin of "ansu-" is not clearly defined.
Usage
Ansuvimab is used for the treatment of Ebola virus disease, a severe and often fatal illness in humans. It works by attaching to the Ebola virus and blocking its ability to infect new cells.
Administration
Ansuvimab is administered intravenously, usually as a single dose. The dosage may vary depending on the patient's medical condition and response to treatment.
Side Effects
Common side effects of Ansuvimab include fever, tachycardia (fast heart rate), and diarrhea. Serious side effects may include allergic reactions, which may cause symptoms such as rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, and trouble breathing.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Ebola virus disease: A severe, often fatal illness in humans, transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
- Intravenous therapy: A therapy that delivers fluids directly into a vein.
See Also
External links
- Medical encyclopedia article on Ansuvimab
- Wikipedia's article - Ansuvimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski